Change in number of shares and votes in Aerocrine

​

With reference to Chapter 4 Section 9 in the Financial Instruments Trading Act, it is hereby announced that subscription without subscription rights in the rights issue in Aerocrine has increased the number of shares and votes in Aerocrine during November 2010 as specified in the table below.

Solna on November 30, 2010

Aerocrine AB (publ.)

For further information, please contact:

Michael Colérus, CFO, +46 8 629 07 85

About Aerocrine Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 a.m. on November the 30th 2010.